Santhera Pharmaceuticals Holding AG Enterprise Value to EBITDA (EV/EBITDA) on July 11, 2025: -11.24

Santhera Pharmaceuticals Holding AG Enterprise Value to EBITDA (EV/EBITDA) is -11.24 on July 11, 2025, a -1,150.66% change year over year. EV/EBITDA ratio compares the enterprise value to the EBITDA; lower suggests more favorable company valuation.
  • Santhera Pharmaceuticals Holding AG 52-week low Enterprise Value to EBITDA (EV/EBITDA) is 2.47 on July 11, 2025, which is 121.95% above the current Enterprise Value to EBITDA (EV/EBITDA).
  • Santhera Pharmaceuticals Holding AG 52-week low Enterprise Value to EBITDA (EV/EBITDA) is -13.69 on July 11, 2025, which is -21.77% below the current Enterprise Value to EBITDA (EV/EBITDA).
  • Santhera Pharmaceuticals Holding AG average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is -2.48.
Key Data
Date Enterprise Value to EBITDA (EV/EBITDA) Free Cash Flow Yield Dividend Yield Market Capitalization